AMRN Q3 2025 Earnings — Amarin Corporation plc Revenue & Financial Results | Market Cap Arena

AMRNAmarin Corporation plc

$310M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+17.4% YoY

Gross Profit

$22M44.7% margin

Operating Income

-$11M-22.4% margin

Net Income

-$8M-15.6% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-31.7%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$660M

Total Liabilities

$201M

Stockholders' Equity

$459M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$42M	+17.4%
Gross Profit	$22M	$16M	+36.4%
Operating Income	-$11M	-$25M	+55.9%
Net Income	-$8M	-$25M	+69.2%

Revenue Segments

Product

$49M98%

Licensing And Royalty

$1M2%

Geographic Segments

UNITED STATES

$41M91%

Europe

$4M9%